A PHASE II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER

Brief description of study

The purpose of the study is to determine the surgical safety and feasibility of atezolizumab plus tiragolumab alone (Atezo and Tira) or in combination with platinum-based chemotherapy (Atezo and Tira and Chemo) as neoadjuvant treatment for patients with previously untreated locally advanced non-small cell lung cancer (NSCLC). The study will also evaluate the effectiveness of the drugs for the following combinations: neoadjuvant Atezo and Tira or Atezo and Tira and Chemo, followed by adjuvant Atezo and Tira or adjuvant platinum-based chemotherapy. The study drugs of Atezo and Tira are investigational, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.